Assenagon Asset Management S.A. Reduces Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Assenagon Asset Management S.A. reduced its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 76.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 476,782 shares of the biopharmaceutical company’s stock after selling 1,561,114 shares during the period. Assenagon Asset Management S.A. owned approximately 0.16% of Amicus Therapeutics worth $4,491,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Xponance Inc. boosted its stake in shares of Amicus Therapeutics by 5.3% in the 2nd quarter. Xponance Inc. now owns 18,555 shares of the biopharmaceutical company’s stock worth $184,000 after buying an additional 936 shares during the last quarter. Hazlett Burt & Watson Inc. boosted its stake in shares of Amicus Therapeutics by 156.9% in the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 1,569 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Amicus Therapeutics by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,727 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 1,884 shares during the last quarter. OLD Second National Bank of Aurora purchased a new position in shares of Amicus Therapeutics in the 3rd quarter worth $26,000. Finally, AlphaCentric Advisors LLC boosted its stake in shares of Amicus Therapeutics by 1.2% in the 3rd quarter. AlphaCentric Advisors LLC now owns 205,000 shares of the biopharmaceutical company’s stock worth $2,189,000 after buying an additional 2,500 shares during the last quarter.

Insider Buying and Selling at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 7,901 shares of Amicus Therapeutics stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $12.50, for a total value of $98,762.50. Following the sale, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $11,083,175. The trade was a 0.88 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 22,901 shares of company stock valued at $259,863 over the last ninety days. 2.20% of the stock is currently owned by company insiders.

Amicus Therapeutics Price Performance

NASDAQ:FOLD opened at $9.41 on Tuesday. The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18. The business’s 50-day simple moving average is $9.68 and its two-hundred day simple moving average is $10.53. The stock has a market cap of $2.81 billion, a PE ratio of -27.68, a P/E/G ratio of 1.25 and a beta of 0.62. Amicus Therapeutics, Inc. has a 52 week low of $8.78 and a 52 week high of $14.03.

Analysts Set New Price Targets

FOLD has been the topic of a number of research reports. Bank of America raised their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, October 17th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a report on Monday, January 13th. Guggenheim raised their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. JPMorgan Chase & Co. raised their target price on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, November 12th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $12.00 target price (down from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $16.88.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.